肥厚型心肌病左心房生理分期与新发房颤风险
本研究基于两个学术转诊中心705例左室收缩功能正常的肥厚型心肌病患者,结合左房压与左房收缩应变构建左心房生理分期系统。中位随访7.5年,新发房颤101例,分期每升高一级,新发房颤风险增加83%。该分期系统在独立外部队列中验证一致,并优于CHARGE-AF和HCM-AF既有风险模型。
要点
- 结合左房压与左房收缩应变进行分期,可反映左房对舒张功能障碍的适应过程。
- 左房分期每升高一级,新发房颤风险显著增加,可辅助房颤监测策略制定。
- 连续超声显示左房分期以稳定或向更高级别进展为主,提示需动态评估。
核心结论
- 左心房生理分期系统可揭示肥厚型心肌病中左房适应进行性舒张功能障碍的机制。
- 该分期与新发房颤风险呈分级相关,可能有助于个体化房颤监测策略。
研究设计与样本
- 多中心回顾性研究,纳入2007年1月至2024年2月两个学术转诊中心的肥厚型心肌病患者。
- 排除瓣膜性心脏病和既往房颤患者,最终纳入705例左室收缩功能正常者。
- 外部验证在独立的425例肥厚型心肌病队列中完成。
主要发现
- 705例患者平均年龄57.6±13.0岁,女性占30.1%,中位随访7.5年。
- 随访期间101例发生新发房颤,分期系统每升高一级的新发房颤校正HR为1.83。
- 该分期系统在CHARGE-AF和HCM-AF风险模型基础上提供增量预测价值。
- 217例患者在基线后4至6年复查超声,39.6%分期稳定,43.8%进展至更高分期或房颤。
关键数值与推荐
- 分期依据:左房压升高(血流动力学负荷)与左房收缩应变(左房内在功能)的组合。
- 新发房颤校正HR:1.83每级递增,95% CI:1.42-2.37,P<0.001。
- 外部验证队列:425例,平均年龄59.7±13.5岁,女性占33.9%。
临床怎么用
- 对肥厚型心肌病患者可结合左房压与左房收缩应变进行左房生理分期评估。
- 左房分期较高的患者可能需要更密切的房颤筛查和随访监测。
局限性
- 回顾性研究设计存在选择偏倚和信息偏倚的可能。
- 左房压力为无创估测而非直接有创测量。
- 两个中心均为学术转诊中心,结果外推至社区人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is pervasive and an independent driver of stroke and death in hypertrophic cardiomyopathy (HCM). Despite guideline recommendations for AF surveillance, effective risk stratification remains elusive, and the hemodynamic and functional states of the left atrium (LA) preceding AF onset remain poorly characterized. OBJECTIVES: We aimed to delineate the hemodynamic and functional states of the LA in HCM, derive a novel LA staging system, and evaluate its prognostic performance for new-onset atrial fibrillation (NOAF). METHODS: This multicenter retrospective study included consecutive HCM patients with normal left ventricular systolic function from January 2007 to February 2024 at 2 academic referral centers. Patients with valvular heart disease or prior AF were excluded. Patients were categorized by combining the presence of elevated LA pressure (hemodynamic load) and LA contractile strain (intrinsic LA function): stage 1 (normal LA pressure and function), stage 2 (relative contractile augmentation for a given LA pressure), stage 3 (loss of relative contractile augmentation despite elevated LA pressure), stage 4 (elevated LA pressure with decreased LA contractile strain), and isolated LA contractile dysfunction. The primary outcome was NOAF. External validation was conducted in an independent HCM cohort. RESULTS: Of 1,856 patients screened, 705 were eligible (mean age 57.6 ± 13.0 years, 30.1% female). During a median follow-up of 7.5 years (Q1-Q3: 3.6-11.0 years), NOAF occurred in 101. The staging system was independently associated with a significant, stepwise increase in the risk of NOAF (adjusted HR: 1.83 per increment; 95% CI: 1.42-2.37; P < 0.001) and conferred incremental predictive value beyond established risk models (CHARGE-AF and HCM-AF). Consistent results were demonstrated in 1-year landmark and competing-risk analyses, as well as in an external validation cohort (n = 425; age 59.7 ± 13.5 years, 33.9% female). Importantly, serial echocardiography performed in 217 patients 4 to 6 years after baseline revealed a predominantly unidirectional evolution of the proposed LA stage, with most patients remaining stable (39.6%) or progressing to higher stages or AF (43.8%). CONCLUSIONS: The proposed LA staging framework offers mechanistic insights into how the LA adapts to progressive diastolic dysfunction in HCM. It is associated with a graded risk of NOAF and may help tailor AF surveillance strategies.
引用
- Lim, Hwang, Kim, et al. Physiological Left Atrial Staging and the Risk of New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2026. PMID: 42714359. doi:10.1016/j.jacc.2026.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。